Traws Pharma, Inc. ( (TRAW) ) has released its Q3 earnings. Here is a breakdown of the information Traws Pharma, Inc. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for respiratory viral diseases, including COVID-19 and influenza.
In its third-quarter 2025 earnings report, Traws Pharma highlighted significant progress in its antiviral programs, including ongoing Phase 2 studies for ratutrelvir, a potential COVID-19 treatment, and advancements in its bird flu and seasonal flu treatment, Tivoxavir Marboxil. The company also reported a notable reduction in costs and the acquisition of significant intellectual property assets.
Key financial metrics for the quarter showed a decrease in cash and cash equivalents to $6.4 million from $21.3 million at the end of 2024. The company reported zero revenue for the quarter, down from $57,000 in the same period last year. However, Traws Pharma managed to reduce its net loss to $4.0 million from $8.5 million in the previous year, driven by decreased research and development and general administrative expenses.
Strategically, Traws Pharma is advancing its antiviral candidates, with ratutrelvir showing promise in reducing COVID-19 rebound and Long COVID risks. Tivoxavir Marboxil is positioned for potential inclusion in government stockpiling initiatives for pandemic preparedness. The company is also seeking partnerships to further develop its legacy oncology assets.
Looking ahead, Traws Pharma remains focused on advancing its clinical trials and exploring strategic partnerships to enhance its pipeline and financial position, with anticipated data from ongoing studies expected by the end of 2025.